Li Zhu

发表

Model-Based Approach for Optimization of Atazanavir Dose Recommendations for HIV-Infected Pediatric Patients

K. Kowalski, R. Bertz, M. Pfister, 2011, Antimicrobial Agents and Chemotherapy.

Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.

D. Grasela, P. Timmins, A. Dennis, 2013, Journal of pharmaceutical sciences.

A convenient strategy to overcome interference in LC‐MS/MS analysis: Application in a microdose absolute bioavailability study

A. Allentoff, Christine S. Huang, R. Pillutla, 2019, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetics and Pharmacodynamics of Atazanavir‐containing Antiretroviral Regimens, with or without Ritonavir, in Patients who are HIV‐positive and Treatment‐naïve

R. Bertz, D. Grasela, A. Persson, 2013, Pharmacotherapy.

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

R. Bertz, Yaoshi Wu, Jenny Zhang, 2011, The Journal of antimicrobial chemotherapy.

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

M. Kozal, R. Leavitt, F. Raffi, 2012, HIV clinical trials.

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

Jason Zhang, P. Statkevich, Yan Feng, 2019, CPT: pharmacometrics & systems pharmacology.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

M. Krystal, R. Bertz, A. Persson, 2012, The Journal of antimicrobial chemotherapy.

CYP2C19 Genotype–Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir‐Boosted Atazanavir in Healthy Subjects

Li Zhu, R. Bertz, Jonathan Uy, 2017, Journal of clinical pharmacology.

Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.

P. Tebas, M. Boffito, R. Bertz, 2011, AIDS patient care and STDs.

Effect of Low‐Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple‐Dose Atazanavir With Ritonavir in Healthy Subjects

R. Bertz, A. Persson, T. Eley, 2011, Journal of clinical pharmacology.

Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.

Peter Timmins, Li Zhu, Nicholas A Meanwell, 2014, Drug discovery today.

A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.

M. Meng, Sam S. Chang, J. Gschwend, 2020 .

In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

N. Meanwell, M. Krystal, J. Kadow, 2012, Antimicrobial Agents and Chemotherapy.

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

Samit R. Joshi, B. Sadler, R. Bertz, 2016, Antimicrobial Agents and Chemotherapy.

Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.

Toshio Shimizu, M. Yunokawa, K. Yonemori, 2022, Journal of Clinical Oncology.

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects

Y. Yazdanpanah, F. Raffi, R. Bertz, 2013, Journal of acquired immune deficiency syndromes.

A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.

M. Meng, Sam S. Chang, J. Gschwend, 2019, Journal of Clinical Oncology.

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

R. Bertz, A. Persson, J. Butterton, 2010, Antiviral therapy.

IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908

N. André, D. Hargrave, A. Gajjar, 2022, Neuro-Oncology.

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908

N. André, D. Hargrave, A. Gajjar, 2023, Neuro-oncology.

Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects

R. Bertz, G. Hanna, M. Furlong, 2015, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection

T. Garimella, R. Bertz, T. Eley, 2017, Clinical Pharmacokinetics.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.

Pharmaceutics, Drug Delivery and Pharmaceutical Technology Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug

D. Grasela, P. Timmins, A. Dennis, 2013 .

Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection

T. Garimella, R. Bertz, T. Eley, 2018, Infectious Diseases and Therapy.